KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Alnylam Pharmaceuticals (ALNY) EBT (2016 - 2026)

Alnylam Pharmaceuticals (ALNY) has disclosed EBT for 17 consecutive years, with $221.7 million as the latest value for Q1 2026.

  • For Q1 2026, EBT rose 9460.35% year-over-year to $221.7 million; the TTM value through Mar 2026 reached $553.1 million, up 274.95%, while the annual FY2025 figure was $323.2 million, 185.63% up from the prior year.
  • EBT hit $221.7 million in Q1 2026 for Alnylam Pharmaceuticals, up from $86.3 million in the prior quarter.
  • Across five years, EBT topped out at $280.6 million in Q3 2025 and bottomed at -$405.9 million in Q3 2022.
  • Average EBT over 5 years is -$81.6 million, with a median of -$108.7 million recorded in 2024.
  • Year-over-year, EBT plummeted 216.63% in 2025 and then surged 9460.35% in 2026.
  • Alnylam Pharmaceuticals' EBT stood at -$207.0 million in 2022, then surged by 33.49% to -$137.7 million in 2023, then tumbled by 40.87% to -$194.0 million in 2024, then soared by 144.47% to $86.3 million in 2025, then surged by 156.96% to $221.7 million in 2026.
  • According to Business Quant data, EBT over the past three periods came in at $221.7 million, $86.3 million, and $280.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.